Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Zhou

P1.15-35 Real World Outcome of Different Administrations Endostar Combined With Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC

Journal of Thoracic Oncology

English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

P2.11-08 Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting With GGNs /Solid Nodules

Journal of Thoracic Oncology

English

P2.04-13 the Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression

Journal of Thoracic Oncology

English

MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Journal of Thoracic Oncology

English

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

Journal of Thoracic Oncology

English

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

Journal of Thoracic Oncology

English

MA11.11 Discrepancy of Tumor Neoantigen Burden Between Primary Lesions and Matched Metastases in Lung Cancer

Journal of Thoracic Oncology

English

P2.01-121 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma

Journal of Thoracic Oncology

English

Protection Against Hepatitis E Virus Infection by Naturally Acquired and Vaccine-Induced Immunity

Clinical Microbiology and Infection

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Zhou

P1.15-35 Real World Outcome of Different Administrations Endostar Combined With Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

P2.11-08 Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting With GGNs /Solid Nodules

P2.04-13 the Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression

MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

MA11.11 Discrepancy of Tumor Neoantigen Burden Between Primary Lesions and Matched Metastases in Lung Cancer

P2.01-121 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma

Protection Against Hepatitis E Virus Infection by Naturally Acquired and Vaccine-Induced Immunity